Saltar al contenido
Merck

P7739

Sigma-Aldrich

Protein kinase A inhibitor fragment 5-24 amide trifluoroacetate salt

≥95% (HPLC), lyophilized powder

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

MDL number:
UNSPSC Code:
41106305
PubChem Substance ID:
NACRES:
NA.32

assay

≥95% (HPLC)

form

lyophilized powder

mol wt

calculated mol wt 2219

composition

Peptide content, ~75%

solubility

H2O: soluble

UniProt accession no.

shipped in

wet ice

storage temp.

−20°C

SMILES string

OC(=O)C(F)(F)F.CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@@H](N)[C@@H](C)O)[C@@H](C)O)[C@@H](C)CC)[C@@H](C)O)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(O)=O)C(N)=O

InChI

1S/C94H149N33O30.C2HF3O2/c1-11-42(3)70(125-86(152)59(31-50-19-14-13-15-20-50)119-85(151)62(36-68(138)139)118-75(141)44(5)111-82(148)58(32-51-24-26-53(132)27-25-51)121-91(157)73(49(10)131)127-87(153)69(96)47(8)129)89(155)113-45(6)76(142)123-63(40-128)78(144)108-38-65(134)115-55(22-17-29-106-93(100)101)81(147)126-72(48(9)130)88(154)109-39-66(135)114-54(21-16-28-105-92(98)99)79(145)116-56(23-18-30-107-94(102)103)80(146)120-61(34-64(95)133)83(149)112-46(7)77(143)124-71(43(4)12-2)90(156)122-60(33-52-37-104-41-110-52)84(150)117-57(74(97)140)35-67(136)137;3-2(4,5)1(6)7/h13-15,19-20,24-27,37,41-49,54-63,69-73,128-132H,11-12,16-18,21-23,28-36,38-40,96H2,1-10H3,(H2,95,133)(H2,97,140)(H,104,110)(H,108,144)(H,109,154)(H,111,148)(H,112,149)(H,113,155)(H,114,135)(H,115,134)(H,116,145)(H,117,150)(H,118,141)(H,119,151)(H,120,146)(H,121,157)(H,122,156)(H,123,142)(H,124,143)(H,125,152)(H,126,147)(H,127,153)(H,136,137)(H,138,139)(H4,98,99,105)(H4,100,101,106)(H4,102,103,107);(H,6,7)/t42-,43-,44-,45-,46-,47+,48+,49+,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,69-,70-,71-,72-,73-;/m0./s1

InChI key

CJBPFVMGYBOAOJ-AYVQDJQPSA-N

Gene Information

human ... PKIA(5569)

Amino Acid Sequence

Thr-Thr-Tyr-Ala-Asp-Phe-Ile-Ala-Ser-Gly-Arg-Thr-Gly-Arg-Arg-Asn-Ala-Ile-His-Asp-NH2

General description

Protein kinase A inhibitor fragment inhibits the protein kinase cAMP-activated catalytic subunit alpha (PRKACA). The gene encoding it is localized on human chromosome 19p13.1. Mutations in the gene encoding protein kinase cAMP-activated catalytic subunit α (PRKACA) have been associated with Cushing′s syndrome.

Biochem/physiol Actions

Binds to the catalytic subunit of protein kinase A (PKA), mimicking the protein substrate

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

The gene encoding the catalytic subunit Ca of cAMP-dependent protein kinase (locus PRKACA) localizes to human chromosome region 19p13. 1
Kjetil T
Genomics (1996)
Activating hotspot L205R mutation in PRKACA and adrenal Cushing's syndrome.
Cao Y
Science (2014)
Barbara Wienen-Schmidt et al.
ACS chemical biology, 14(12), 2585-2594 (2019-10-23)
Drug optimization is guided by biophysical methods with increasing popularity. In the context of lead structure modifications, the introduction of methyl groups is a simple but potentially powerful approach. Hence, it is crucial to systematically investigate the influence of ligand
Barbara Wienen-Schmidt et al.
ChemMedChem, 16(1), 292-300 (2020-10-09)
In lead optimization, protein crystallography is an indispensable tool to analyze drug binding. Binding modes and non-covalent interaction inventories are essential to design follow-up synthesis candidates. Two protocols are commonly applied to produce protein-ligand complexes: cocrystallization and soaking. Because of

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico